Sara P. Ginzberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sara P. Ginzberg has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
Heather Wachtel
Department of Surgery Hospital of the University of Pennsylvania Philadelphia Pennsylvania USA
11 shared publications- Heather Wachtel
Department of Surgery, University of Pennsylvania Health System, Philadelphia, Pennsylvania
10 shared publications Rachel R. Kelz
Department of Surgery, University of Pennsylvania Health System, Philadelphia
10 shared publicationsJacqueline M. Soegaard Ballester
Department of Surgery Hospital of the University of Pennsylvania Philadelphia Pennsylvania USA
8 shared publications- Jacqueline M. Soegaard Ballester
Department of Surgery, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA
7 shared publications - Jesse E. Passman
Department of Surgery University of Pennsylvania Philadelphia Pennsylvania USA
7 shared publications
Latest Publications
- 11 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
Unique Considerations in Care Delivery for Early-Onset Gastrointestinal Cancers: A Narrative Review
The incidence of early-onset gastrointestinal (GI) cancers, typically defined by diagnosis before age 50 years, is rapidly rising in the United States and around the world. Although the underlying drivers of this trend are incompletely understood, emerging evidence suggests that environmental exposures and lifestyle factors play key roles. Patients with early-onset GI cancers face unique challenges over the course of their care. Young patients often experience diagnostic delays, present at more advanced stages, and have more aggressive tumor biology than their older counterparts. Patients with early-onset cancers are also frequently offered more intensive treatment, although with unclear benefit. Beyond these medical differences, early-onset patients may experience increased psychosocial distress compared with older patients, including higher rates of financial toxicity, childcare needs, depression and anxiety, concerns about relationships and sexuality, distress about fertility consequences, and disruption of educational and career trajectories. However, current clinical practice patterns often fail to adequately address the unique needs of early-onset patients. Although several large academic centers have modeled the implementation of specialized multidisciplinary programs to care for patients with early-onset colorectal cancer, broad access to these programs remains limited. Future work must evaluate the scalability of these models to other GI cancer sites across diverse care settings, as well as improve equitable access to timely diagnosis and optimal care for this growing patient population.
- 11 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
Unique Considerations in Care Delivery for Early-Onset Gastrointestinal Cancers: A Narrative Review
The incidence of early-onset gastrointestinal (GI) cancers, typically defined by diagnosis before age 50 years, is rapidly rising in the United States and around the world. Although the underlying drivers of this trend are incompletely understood, emerging evidence suggests that environmental exposures and lifestyle factors play key roles. Patients with early-onset GI cancers face unique challenges over the course of their care. Young patients often experience diagnostic delays, present at more advanced stages, and have more aggressive tumor biology than their older counterparts. Patients with early-onset cancers are also frequently offered more intensive treatment, although with unclear benefit. Beyond these medical differences, early-onset patients may experience increased psychosocial distress compared with older patients, including higher rates of financial toxicity, childcare needs, depression and anxiety, concerns about relationships and sexuality, distress about fertility consequences, and disruption of educational and career trajectories. However, current clinical practice patterns often fail to adequately address the unique needs of early-onset patients. Although several large academic centers have modeled the implementation of specialized multidisciplinary programs to care for patients with early-onset colorectal cancer, broad access to these programs remains limited. Future work must evaluate the scalability of these models to other GI cancer sites across diverse care settings, as well as improve equitable access to timely diagnosis and optimal care for this growing patient population.
- Open Access
- 22 July 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 260
Validation of a novel risk stratification model for primary aldosteronism
- 22 July 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 260
Open AccessValidation of a novel risk stratification model for primary aldosteronism
- Open Access
Contemporary trends in utilization of metastasectomy in the era of targeted and immunotherapies
Background: Metastasectomy is a useful adjunct in the management of metastatic cancer. Widespread adoption of novel targeted and immunotherapies has improved the survival profiles of multiple malignancies, which has potentially altered the role of metastasectomy. This study aimed to characterize trends in metastasectomy across five primary cancers eligible for these therapies.Methods: The National Inpatient Sample was used to identify patients who underwent metastasectomy in the United States (2016–2021). Patients with procedure codes for resection of the lung, liver, adrenal gland, brain, or small bowel and concurrent diagnosis codes for secondary malignant neoplasm of that site were included. Subjects were subcategorized by primary malignancy: colorectal cancer, lung cancer, breast cancer, melanoma, or renal cancer. Sample weights were used to produce national estimates, which were incidence adjusted by primary malignancy. Trends in utilization were calculated with average annual percent change (AAPC) and linear regression coefficients.Results: Colorectal cancer was the most frequent indication for metastasectomy (n = 57,644 cases), followed by lung cancer (n = 55,090 cases), breast cancer (n = 12,616 cases), renal cancer (n = 8427 cases), and melanoma (n = 5658 cases). Utilization of metastasectomy increased over the study period for breast cancer (AAPC, +10.6%; p = .013) and melanoma (AAPC, +8.3%; p = .040) but did not change for lung cancer (AAPC, −1.6%; p = .26), colorectal cancer (AAPC, +0.3%; p = .83), or renal cancer (AAPC, +2.3%; p = .36).Conclusions: Between 2016 and 2021, utilization of metastasectomy increased significantly for melanoma and breast cancer. The role of metastasectomy will likely continue to develop as new treatment protocols improve survival profiles for patients with metastatic disease.
Open AccessContemporary trends in utilization of metastasectomy in the era of targeted and immunotherapies
Background: Metastasectomy is a useful adjunct in the management of metastatic cancer. Widespread adoption of novel targeted and immunotherapies has improved the survival profiles of multiple malignancies, which has potentially altered the role of metastasectomy. This study aimed to characterize trends in metastasectomy across five primary cancers eligible for these therapies.Methods: The National Inpatient Sample was used to identify patients who underwent metastasectomy in the United States (2016–2021). Patients with procedure codes for resection of the lung, liver, adrenal gland, brain, or small bowel and concurrent diagnosis codes for secondary malignant neoplasm of that site were included. Subjects were subcategorized by primary malignancy: colorectal cancer, lung cancer, breast cancer, melanoma, or renal cancer. Sample weights were used to produce national estimates, which were incidence adjusted by primary malignancy. Trends in utilization were calculated with average annual percent change (AAPC) and linear regression coefficients.Results: Colorectal cancer was the most frequent indication for metastasectomy (n = 57,644 cases), followed by lung cancer (n = 55,090 cases), breast cancer (n = 12,616 cases), renal cancer (n = 8427 cases), and melanoma (n = 5658 cases). Utilization of metastasectomy increased over the study period for breast cancer (AAPC, +10.6%; p = .013) and melanoma (AAPC, +8.3%; p = .040) but did not change for lung cancer (AAPC, −1.6%; p = .26), colorectal cancer (AAPC, +0.3%; p = .83), or renal cancer (AAPC, +2.3%; p = .36).Conclusions: Between 2016 and 2021, utilization of metastasectomy increased significantly for melanoma and breast cancer. The role of metastasectomy will likely continue to develop as new treatment protocols improve survival profiles for patients with metastatic disease.
- 1 December 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (12) , 1705-1713
Disparities in the Use of Preoperative Breast Magnetic Resonance Imaging After Breast Cancer Diagnosis
PURPOSE: Preoperative magnetic resonance imaging (MRI) after breast cancer diagnosis is increasingly used to improve locoregional staging, particularly among women with dense breasts, extensive ductal carcinoma in situ, and lobular histology. The goals of this study were to (1) assess whether use of preoperative MRI varies by race and insurance type; and (2) determine whether preoperative MRI is associated with downstream surgical management. MATERIALS AND METHODS: We performed a retrospective cohort study of women with stage 0-III breast cancer who were treated with surgical resection within our academic health system (2016-2019). Patients were categorized by race and insurance type. The primary outcome was receipt of preoperative MRI. Secondary outcomes included surgery extent (lumpectomy v mastectomy) and receipt of a second operation. RESULTS: A total of 1,410 women (27% Black, 73% White; 67% private insurance, 26% Medicare, 6% Medicaid) were included. Black patients were significantly less likely to undergo preoperative MRI than White patients (odds ratio [OR], 0.54 [95% CI, 0.38 to 0.76]; P < .001). There was no association between insurance type and preoperative MRI (Medicare v private: OR, 0.77 [95% CI, 0.52 to 1.15]; P = .208; Medicaid v private: OR, 0.67 [95% CI, 0.36 to 1.25]; P = .210). White patients who underwent preoperative MRI were less likely to undergo lumpectomy versus those who did not (OR, 0.53 [95% CI, 0.37 to 0.76]; P < .001). Likelihood of re-excision was lower for Black women who had undergone MRI versus those who had not (OR, 0.43 [95% CI, 0.20 to 0.93]; P = .031). CONCLUSION: Black patients were less likely than White patients to undergo preoperative MRI, yet Black women who underwent MRI were less likely to require re-excision. Standardizing preoperative MRI use may mitigate provider- and system-level biases and promote more equitable care.
- 1 December 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (12) , 1705-1713
Disparities in the Use of Preoperative Breast Magnetic Resonance Imaging After Breast Cancer Diagnosis
PURPOSE: Preoperative magnetic resonance imaging (MRI) after breast cancer diagnosis is increasingly used to improve locoregional staging, particularly among women with dense breasts, extensive ductal carcinoma in situ, and lobular histology. The goals of this study were to (1) assess whether use of preoperative MRI varies by race and insurance type; and (2) determine whether preoperative MRI is associated with downstream surgical management. MATERIALS AND METHODS: We performed a retrospective cohort study of women with stage 0-III breast cancer who were treated with surgical resection within our academic health system (2016-2019). Patients were categorized by race and insurance type. The primary outcome was receipt of preoperative MRI. Secondary outcomes included surgery extent (lumpectomy v mastectomy) and receipt of a second operation. RESULTS: A total of 1,410 women (27% Black, 73% White; 67% private insurance, 26% Medicare, 6% Medicaid) were included. Black patients were significantly less likely to undergo preoperative MRI than White patients (odds ratio [OR], 0.54 [95% CI, 0.38 to 0.76]; P < .001). There was no association between insurance type and preoperative MRI (Medicare v private: OR, 0.77 [95% CI, 0.52 to 1.15]; P = .208; Medicaid v private: OR, 0.67 [95% CI, 0.36 to 1.25]; P = .210). White patients who underwent preoperative MRI were less likely to undergo lumpectomy versus those who did not (OR, 0.53 [95% CI, 0.37 to 0.76]; P < .001). Likelihood of re-excision was lower for Black women who had undergone MRI versus those who had not (OR, 0.43 [95% CI, 0.20 to 0.93]; P = .031). CONCLUSION: Black patients were less likely than White patients to undergo preoperative MRI, yet Black women who underwent MRI were less likely to require re-excision. Standardizing preoperative MRI use may mitigate provider- and system-level biases and promote more equitable care.
- 28 October 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 239, 116048
Demystifying delays: Factors associated with timely treatment of adrenocortical carcinoma
- 28 October 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 239, 116048
Demystifying delays: Factors associated with timely treatment of adrenocortical carcinoma
- 1 October 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (10) , 1367-1375
Racial Disparities and Strategies for Improving Equity in Diagnostic Follow-Up for Abnormal Screening Mammograms
PURPOSE: Black and White women undergo screening mammography at similar rates, but racial disparities in breast cancer outcomes persist. To assess potential contributors, we investigated delays in follow-up after abnormal imaging by race/ethnicity. METHODS: Women who underwent screening mammography at our urban academic center from January 2015 to February 2018 and received a Breast Imaging Reporting and Data System 0 assessment were included. Kaplan-Meier estimates described distributions of time between diagnostic events from (1) screening to diagnostic imaging and (2) diagnostic imaging to biopsy. Multivariable logistic regression models estimated the associations between race/ethnicity and receipt of follow-up within 15 and 30 days. RESULTS: Two thousand five hundred and fifty-four women were included (48.6% non-Hispanic [NH] Black, 38.2% NH White, 13.1% other/unknown). Median time between screening and diagnostic imaging varied by race/ethnicity (White: 7 days [IQR, 2-14]; Black: 12 days [IQR, 7-23]; other/unknown: 9 days [IQR, 5-21]). There were similar disparities in days between diagnostic imaging and biopsy (White: 12 [IQR, 7-24]; Black: 21 [IQR, 13-37]; other/unknown: 16 [IQR, 9-30]) and between screening and biopsy (White: 20 [IQR, 11-41]; Black: 35 [IQR, 22-63]; other/unknown: 27.5 [IQR, 17-42]). After adjustment, odds of diagnostic imaging follow-up within 15 days of screening were lower for Black versus White women (odds ratio, 0.59 [95% CI, 0.44 to 0.80]; P < .001). CONCLUSION: In this diverse cohort, disparities in timely diagnostic follow-up after abnormal breast screening were observed, with Black women waiting 1.75 times as long as White women to obtain a tissue diagnosis. National guidelines for time to diagnostic follow-up may facilitate more timely breast cancer care and potentially affect outcomes.
- 1 October 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (10) , 1367-1375
Racial Disparities and Strategies for Improving Equity in Diagnostic Follow-Up for Abnormal Screening Mammograms
PURPOSE: Black and White women undergo screening mammography at similar rates, but racial disparities in breast cancer outcomes persist. To assess potential contributors, we investigated delays in follow-up after abnormal imaging by race/ethnicity. METHODS: Women who underwent screening mammography at our urban academic center from January 2015 to February 2018 and received a Breast Imaging Reporting and Data System 0 assessment were included. Kaplan-Meier estimates described distributions of time between diagnostic events from (1) screening to diagnostic imaging and (2) diagnostic imaging to biopsy. Multivariable logistic regression models estimated the associations between race/ethnicity and receipt of follow-up within 15 and 30 days. RESULTS: Two thousand five hundred and fifty-four women were included (48.6% non-Hispanic [NH] Black, 38.2% NH White, 13.1% other/unknown). Median time between screening and diagnostic imaging varied by race/ethnicity (White: 7 days [IQR, 2-14]; Black: 12 days [IQR, 7-23]; other/unknown: 9 days [IQR, 5-21]). There were similar disparities in days between diagnostic imaging and biopsy (White: 12 [IQR, 7-24]; Black: 21 [IQR, 13-37]; other/unknown: 16 [IQR, 9-30]) and between screening and biopsy (White: 20 [IQR, 11-41]; Black: 35 [IQR, 22-63]; other/unknown: 27.5 [IQR, 17-42]). After adjustment, odds of diagnostic imaging follow-up within 15 days of screening were lower for Black versus White women (odds ratio, 0.59 [95% CI, 0.44 to 0.80]; P < .001). CONCLUSION: In this diverse cohort, disparities in timely diagnostic follow-up after abnormal breast screening were observed, with Black women waiting 1.75 times as long as White women to obtain a tissue diagnosis. National guidelines for time to diagnostic follow-up may facilitate more timely breast cancer care and potentially affect outcomes.
- 1 August 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (8) , 980-989
Revisiting the Relationship Between Tumor Size and Risk in Well-Differentiated Thyroid Cancer
Large tumor size is associated with poorer outcomes in well-differentiated thyroid cancer (WDTC), yet it remains unclear whether size >4 cm alone confers increased risk, independent of other markers of aggressive disease. The goal of this study was to assess the relationship between tumor size, other high-risk histopathologic features, and survival in WDTC, and to evaluate the significance of 4 cm as a cutoff for management decisions. Patients with WDTC were identified from the National Cancer Database (2010-2015) and categorized by tumor size [i.e., small (≤4 cm) or large (>4 cm)] and presence of high-risk histopathologic features (e.g., extrathyroidal extension). First, propensity score matching was used to identify patients who were similar across all other observed characteristics except for small vs. large tumor size, and a multivariable Cox proportional hazards model was used to estimate the relationship between tumor size and survival. Second, we assessed whether the presence of high-risk features demonstrate conditional effects on survival based on the presence of tumor size >4 cm using an interaction term. Finally, additional models assessed the relationship between incremental 1 cm increases in tumor size and survival. Analyses were repeated using a validation cohort from the Surveillance, Epidemiology, and End Results Program (2008-2013). Of 193,133 patients in the primary cohort, 7.9% had tumors >4 cm, and 30% had at least one high-risk feature. After matching, tumor size >4 cm was independently associated with worse survival (HR 1.63, p4 cm and one or more other high-risk features together yielded worse survival than either size >4 cm alone (MMD: 0.70, p<0.001) or other high-risk features alone (MMD: 0.49, p<0.001). When assessed in 1 cm increments, the largest increases in hazard of death occurred at 2 cm and 5 cm, not 4 cm. Results from the validation cohort were largely consistent with our primary findings. Concomitant high-risk features confer worse survival than large tumor size alone, and a 4 cm cutoff is not associated with the greatest increase in risk. These findings support a more nuanced approach to tumor size in the management of WDTC.
- 1 August 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (8) , 980-989
Revisiting the Relationship Between Tumor Size and Risk in Well-Differentiated Thyroid Cancer
Large tumor size is associated with poorer outcomes in well-differentiated thyroid cancer (WDTC), yet it remains unclear whether size >4 cm alone confers increased risk, independent of other markers of aggressive disease. The goal of this study was to assess the relationship between tumor size, other high-risk histopathologic features, and survival in WDTC, and to evaluate the significance of 4 cm as a cutoff for management decisions. Patients with WDTC were identified from the National Cancer Database (2010-2015) and categorized by tumor size [i.e., small (≤4 cm) or large (>4 cm)] and presence of high-risk histopathologic features (e.g., extrathyroidal extension). First, propensity score matching was used to identify patients who were similar across all other observed characteristics except for small vs. large tumor size, and a multivariable Cox proportional hazards model was used to estimate the relationship between tumor size and survival. Second, we assessed whether the presence of high-risk features demonstrate conditional effects on survival based on the presence of tumor size >4 cm using an interaction term. Finally, additional models assessed the relationship between incremental 1 cm increases in tumor size and survival. Analyses were repeated using a validation cohort from the Surveillance, Epidemiology, and End Results Program (2008-2013). Of 193,133 patients in the primary cohort, 7.9% had tumors >4 cm, and 30% had at least one high-risk feature. After matching, tumor size >4 cm was independently associated with worse survival (HR 1.63, p4 cm and one or more other high-risk features together yielded worse survival than either size >4 cm alone (MMD: 0.70, p<0.001) or other high-risk features alone (MMD: 0.49, p<0.001). When assessed in 1 cm increments, the largest increases in hazard of death occurred at 2 cm and 5 cm, not 4 cm. Results from the validation cohort were largely consistent with our primary findings. Concomitant high-risk features confer worse survival than large tumor size alone, and a 4 cm cutoff is not associated with the greatest increase in risk. These findings support a more nuanced approach to tumor size in the management of WDTC.
- 3 June 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (6) , e2414329
Surgeon and Surgical Trainee Experiences After Adverse Patient Events
Medical errors are estimated to be the third most common cause of death in the US, with more than 250 000 deaths attributable to medical errors annually.1,2 Nearly all physicians report having made at least 1 error during their career.3 Despite the frequency of medical errors, it can be very disturbing for physicians to realize that they have unintentionally harmed a patient.4
- 3 June 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (6) , e2414329
Surgeon and Surgical Trainee Experiences After Adverse Patient Events
Medical errors are estimated to be the third most common cause of death in the US, with more than 250 000 deaths attributable to medical errors annually.1,2 Nearly all physicians report having made at least 1 error during their career.3 Despite the frequency of medical errors, it can be very disturbing for physicians to realize that they have unintentionally harmed a patient.4
- 7 February 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 234, 19-25
Sex differences and racial/ethnic disparities in the presentation and treatment of medullary thyroid cancer
- 7 February 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 234, 19-25
Sex differences and racial/ethnic disparities in the presentation and treatment of medullary thyroid cancer
- 29 December 2023
- Published by Elsevier in Endocrine Practice
- Vol. 30 (4) , 305-310
Assessing the Frequency of Deferrable Thyroid Nodule Biopsies to De-escalate Low-Value Care
- 29 December 2023
- Published by Elsevier in Endocrine Practice
- Vol. 30 (4) , 305-310
Assessing the Frequency of Deferrable Thyroid Nodule Biopsies to De-escalate Low-Value Care